Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to $722000.0.

  • Pulmonx's Net Cash Flow rose 2396666.67% to $722000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year increase of 14279.72%. This contributed to the annual value of -$12.7 million for FY2024, which is 3029.59% up from last year.
  • Latest data reveals that Pulmonx reported Net Cash Flow of $722000.0 as of Q3 2025, which was up 2396666.67% from $1.5 million recorded in Q2 2025.
  • Pulmonx's 5-year Net Cash Flow high stood at $8.6 million for Q1 2023, and its period low was -$39.7 million during Q4 2021.
  • Moreover, its 5-year median value for Net Cash Flow was -$8.6 million (2023), whereas its average is -$8.2 million.
  • In the last 5 years, Pulmonx's Net Cash Flow crashed by 159817.94% in 2021 and then soared by 2396666.67% in 2025.
  • Quarter analysis of 5 years shows Pulmonx's Net Cash Flow stood at -$39.7 million in 2021, then soared by 73.64% to -$10.5 million in 2022, then dropped by 6.58% to -$11.1 million in 2023, then skyrocketed by 166.37% to $7.4 million in 2024, then crashed by 90.24% to $722000.0 in 2025.
  • Its Net Cash Flow was $722000.0 in Q3 2025, compared to $1.5 million in Q2 2025 and $3.8 million in Q1 2025.